Technical Analysis for COLL - Collegium Pharmaceutical, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 2.19% | |
| Gapped Down | Weakness | -0.18% | |
| MACD Bullish Signal Line Cross | Bullish | -3.58% | |
| NR7 | Range Contraction | -3.58% | |
| Narrow Range Bar | Range Contraction | -3.58% | |
| Inside Day | Range Contraction | -3.58% | |
| Inside Day | Range Contraction | -3.24% | |
| NR7 | Range Contraction | -3.94% | |
| Narrow Range Bar | Range Contraction | -3.94% |
| Alert | Time |
|---|---|
| Possible Inside Day | 1 day ago |
| Up 3% | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 2% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Get a Trading Assistant
- Earnings date: 06/04/2024
Collegium Pharmaceutical, Inc. Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Disease Pain Organic Compounds Chemical Compounds Euphoriants Chronic Pain Opioids Ethers Platform Technology Attention Deficit Hyperactivity Disorder Morphinans Hyperactivity Disorder Treatment Of Chronic Pain Methylphenidate Phenols Hydrocodone Morphine Oxycodone Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.95 |
| 52 Week Low | 20.835 |
| Average Volume | 433,737 |
| 200-Day Moving Average | 30.16 |
| 50-Day Moving Average | 36.31 |
| 20-Day Moving Average | 34.44 |
| 10-Day Moving Average | 33.65 |
| Average True Range | 1.34 |
| RSI (14) | 42.53 |
| ADX | 27.94 |
| +DI | 13.48 |
| -DI | 31.32 |
| Chandelier Exit (Long, 3 ATRs) | 34.58 |
| Chandelier Exit (Short, 3 ATRs) | 34.44 |
| Upper Bollinger Bands | 38.36 |
| Lower Bollinger Band | 30.52 |
| Percent B (%b) | 0.33 |
| BandWidth | 22.76 |
| MACD Line | -0.83 |
| MACD Signal Line | -0.78 |
| MACD Histogram | -0.0462 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 35.01 | ||||
| Resistance 3 (R3) | 34.92 | 34.21 | 34.70 | ||
| Resistance 2 (R2) | 34.21 | 33.73 | 34.25 | 34.59 | |
| Resistance 1 (R1) | 33.68 | 33.44 | 33.94 | 33.76 | 34.49 |
| Pivot Point | 32.97 | 32.97 | 33.10 | 33.01 | 32.97 |
| Support 1 (S1) | 32.43 | 32.49 | 32.70 | 32.52 | 31.79 |
| Support 2 (S2) | 31.72 | 32.20 | 31.76 | 31.69 | |
| Support 3 (S3) | 31.19 | 31.72 | 31.58 | ||
| Support 4 (S4) | 31.27 |
